“Longevity is a complex game,” said Dr. Robert Hariri, founder of Celularity. “The first step in achieving longevity is to eliminate the cause of premature death and then renew the long-running body system to improve human life.”

Celularity is a biotechnology company in the United States that develops placental stem cells. The company extracts stem cells from the placenta left behind by human production, and treats autoimmune diseases and degenerative diseases through placental stem cells. It aims to enhance human immunity and improve human life. .

Robert Hariri is the founder and CEO of Celularity, a well-known scholar in the field of regenerative medicine. He founded Human Longevity with genomics leader Craig Venter before creating Celularity.

Twelve years ago, Robert Hariri met Dr. Peter Diamandis while driving his own jet to perform a 2000-mile flight in Las Cruces, New Mexico. Dr. Peter Diamandis is the founder of the X Prize Foundation, an outstanding representative dedicated to civil space flight. The two talks first talked about the bio-placenta from the power of the aircraft. This conversation laid the foundation for the two people to finally create Celularity.

Dr. Robert Hariri was the founder and chairman of Celgene, the global biopharmaceutical company, responsible for Cellgene's cell therapy program. In 2016, Celgene alone separated the placental stem cell business. Dr. Robert Hariri collaborated with Dr. Peter Diamandis to form the spin-off company Cellularity, which is committed to using placental stem cells to delay human aging and has a slogan of “extended life”.

Some members of Celularity's board of directors (picture from the official website)

In February 2018, Celularity received $250 million in financing from Celgene and was promoted to a unicorn. In addition to Dr. Robert Hariri, CEO and Dr. Peter Diamandis, Vice Chairman of the Board of Directors, the company's luxury star management team includes Mr. Bill Maris from former Google Venture Capital CEO, former Apple CEO John Sculley and former US Member of the FDA Director Dr. Andrew Von Eschenbach.

Back in the 1980s, when Robert Hariri was a young neurosurgeon at Cornell University, he discovered that the placenta developed much faster than the fetus during the ultrasound examination of the eldest daughter during pregnancy. Contains primitive cells that can divide and differentiate into other types of cells: stem cells. This speculation proved to be correct later, and the placenta is a stem cell factory.

Dr. Robert Hariri (image from Forbes)

However, the stem cells used in medical research at that time were mostly taken from the cord blood of newborns, and the extraction of stem cells from the placenta of the fetus faced enormous moral pressure. In 1997, Robert Hariri left Cornell and began to quietly collect the placenta and extract its stem cells to regenerate it. Later, Robert Hariri used this technology to attract the attention of cancer pharmaceutical giant Celgene. Celgene bought the technology for $45 million, and Robert Hariri became one of Celgene's leaders.

It has been shown that the stem cell function in the placenta is identical to that in the cord blood, and the number of stem cells in the placenta is ten times that of cord blood. But so far, the stem cells in the only FDA-approved stem cell-derived products are only from cord blood.

In the next ten years of work at Celgene, Robert Hariri has found treatments for complex diseases such as Crohn's disease, arthritis and stroke through stem cells extracted from the placenta. Of the nine clinical trials registered for the treatment of human diseases, four have been completed.

After studying these diseases, Robert Hariri found that many diseases today, such as cancer, Crohn's disease, arthritis and Alzheimer's disease, are actually a disease of the disease: aging! The cure for aging is to use stem cells.

Stem cells are a class of pluripotent cells that can differentiate into multiple functional cells. Currently, stem cell transplantation is considered to be the standard of more than 80 diseases, such as leukemia and the treatment of some rare diseases are inseparable from stem cells.

From the clinical data analysis of Celgene's cancer, the stem cell clusters in the bone marrow of most patients decreased exponentially with age, from 1 in 20,000 in infancy to 1 in 20 million in 80 years. Robert Hariri envisions the use of stem cell injections to refresh the body's muscles, reshape the body's organs, and ultimately achieve longevity.

The clinical data also fits this hypothesis, and the lifespan of sexually mature mice after receiving monthly stem cells is extended by 30%-40%. Although the data of mice cannot be directly mapped to humans, this data also indicates that stem cells do have the effect of prolonging life and bring new possibilities for human longevity in the future. Robert Hariri said that one of the company's goals is to make human beings 100 years old as the new 60 years old, and the topic around longevity will always be the mainstream.

Celularity currently has more than a dozen cell therapies in preclinical and IDNA phases. In addition to using cell therapy to treat a variety of degenerative diseases, Cellularity also uses placental biomaterials to make portable and recyclable products that can be used to restore injured tissues. may. Two products, BIOVANCE and INTERFYL, are currently available for the treatment of severe skin wounds and burns, and are of great value in surgery and plastic surgery.

Celularity pioneered the method of regenerating whole organs and organs through the placenta. He worked with giant companies such as United Therapeutics to bring organ regeneration to market.

In addition, Celularity has the most comprehensive cord blood and placental blood bank, which provides patients with the stem cells needed for daily treatment.

All kinds of practices are to make the placenta useable, no longer abandoned or eaten. According to statistics, about 4 million placentas are disposed of every year in American hospitals, and Celularity “does its best” to purchase these wasted placentas to maximize the medical value of the placenta.

Celularity Cellular Immunotherapy Product Pipeline (Photo from official website)

It is worth mentioning that Celularity tries to combine embryonic stem cells with today's hot CAR-T technology to replace the immune cells used by CAR-T with placental stem cells, which means such CAR-T cells. All people with the same type of cell line can be applied without immunological rejection and become allogeneic CAR-T therapy.

Moreover, this cellular immunotherapy using allogeneic CAR-T is expected to be one of the ways to reduce the cost of this technology. CAR-T treatment is currently starting at $373,000 per patient, and Celularity is developing the world's first homologous CAR-T cell receptor product. The universal CAR-T developed using placental cells will create a standardized product that does not theoretically cause an attack on the patient's own immune system. This product is awaiting FDA approval, and post-marketing treatment costs are expected to be more affordable than autologous CAR-T.

Celularity has licensed 50 potential CAR-T structures from California biotechnology company Sorrento Therapeutics to design cells for a wide range of immunotherapeutic applications, including proprietary antibodies and chimeric antigen receptor (CAR) constructs that will make Celularity Became the first company in the world to offer a suite of immunotherapeutic products for new targets for cancer and immune diseases.

In addition, Celularity has discovered a natural killer cell from the placenta and is actively developing therapeutic uses.

However, stem cell therapy has not yet been approved in the United States, and internationally, it is also expensive. Prices in China are generally around $40,000, India's placental stem cell treatment costs about $25,000, and Mexico's cost is about $25,000.

In the current hot cell immunotherapy field, China is represented by the legendary Nanjing creature, which is the first Chinese company to apply for CDE to accept CAR-T products according to the “New Class 1 drug for therapeutic biological products”.

The legendary biology of Nanjing chose BDMA as the target of CAR-T cell therapy, avoiding the competitive flood of CAR-T research and development on the market with CD19 as a hot target. But compared to Celularity's placental stem cell CAR-T, Nanjing legendary organisms choose traditional autologous CAR-T cells, which also means a lot of research costs. Celularity, the only company that uses the same allogeneic placenta platform, extracts stem cells from any placenta and injects it into any audience. In theory, immune rejection does not occur. This means that the cell source channel is widened, the cost of research is reduced, and treatment will be more affordable and immediate.

A foreign biotech company called Cellectis is the pioneer in the international adoption of allogeneic CAR-T. The company already has three products approved by the FDA for clinical trials.

The most urgent problem to be solved with allogeneic CAR is immune rejection, and Cellectis eliminates allogeneic immune rejection by eliminating genes that cause allogeneic immune responses. This is different from the CAR-T cell receptor that Celularity directly uses stem cell culture. The stem cells extracted from the embryo, specifically mesenchymal stem cells (MSC), which have stem cells All commonalities, whether autologous or allogeneic mesenchymal stem cells, generally do not cause an immune response in the host. This reduces the process of eliminating genes and achieves the same therapeutic effect.

In addition to the application of placental stem cells in the field of CAR-T immunotherapy, Celularity also occupies a certain share in the treatment of scald treatment and plastic surgery. The same type of company, in China, as a case of the United States, the company based on genetic testing data, providing users with reference to beauty and fitness, this combination of genes to provide medical beauty services is now The way most medical institutions take it.

Foreign countries such as Syneron Candela in the United States, a leading global non-surgical cosmetic equipment company, provide services that include skin contours, hair removal, and wrinkle reduction to improve skin appearance. Relatively speaking, Celularity provides higher barriers to medical and aesthetic services based on placental stem cells, and has a broader application prospect in the future. The medical and aesthetic fields involved are more large-scale surgical applications such as burns and plastic surgery.

Studies have shown that in human life, stem cells are destroyed by environmental exposure, gradually reducing their quantity and efficiency, thus affecting our own repair ability and longevity. If we can continue to supplement our stem cells, this is enhanced. It is possible to have immunity and increase life expectancy, and the placenta we were born at is just the most effective tissue for extracting stem cells. Why waste it?

Although the use of the placenta for medical research is controversial, with the development of society, more and more ethicists and doctors believe that placental stem cells are moral, because newborns no longer need it, and traditionally it It was discarded after birth. Stem cells can provide a new source of renewable cells for the body to treat many medical diseases, and effective placental stem cell therapy has been shown to significantly improve many medical problems, so there is a broad medical prospect in the use of placental stem cells.

PC Board Venlo Greenhouse

Venlo structure is a popular one at present. This architecture uses horizontal girder as main bearer, forming a stable structure with columns. There is consolidation between horizontal girder and column, and hinge is used to connect column and foundation.
In Venlo greenhouse, foundation is made of reinforced concrete and the side wall is made of brick or reinforced concrete plate. The steel frame always use hot dip galvanized light steel. Roof beam adopts horizontal girder structure and using herringbone connection. The horizontal girder bears 2 or more roofs, which is made of aluminum alloy. This material is used as roof structure material and also glass inlay material. Other beams using gutter style to minimize the section. Delighting material of the roof and side wall using the hollow double-layer or multilayer PC board.
PC board is mainly made of PC/PET/PMMA/PP materials, it need sun screen coating to resist ultraviolet resist and ageing, and it is also required to be anti condensation and antidrug.
As a kind of light material, use PC board can greatly reduce the weight of greenhouse structure, and corresponding reduced the size of the steel frame, which saving the cost of steel.

Pc Board Venlo Greenhouse,Venlo Greenhouse,Venlo Type Pc Sheet Greenhouse

JIANGSU SKYPLAN GREENHOUSE TECHNOLOGY CO.,LTD , https://www.skyplantgreenhouse.com